Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

st. mary's medical park pharmacy - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated ( see warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome ( see warnings and dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydro

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

northwind pharmaceuticals - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated ( see   warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome ( see   warnings   and   dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 200 mg - capsule, hard - excipient ingredients: magnesium stearate; erythrosine; pregelatinised maize starch; colloidal anhydrous silica; lactose monohydrate; purified talc; sodium lauryl sulfate; purified water; gelatin; titanium dioxide; brilliant blue fcf - fluconazole, given orally, is indicated for treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note. data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note. it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 150 mg - capsule, hard - excipient ingredients: brilliant blue fcf; pregelatinised maize starch; gelatin; colloidal anhydrous silica; magnesium stearate; sodium lauryl sulfate; purified talc; lactose monohydrate; purified water; titanium dioxide - fluconazole, given orally, is indicated for treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note. data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note. it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 50 mg - capsule, hard - excipient ingredients: purified talc; magnesium stearate; pregelatinised maize starch; colloidal anhydrous silica; erythrosine; titanium dioxide; lactose monohydrate; brilliant blue fcf; purified water; sodium lauryl sulfate; gelatin - fluconazole, given orally, is indicated for treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note. data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note. it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - solifenacin succinate, quantity: 10 mg - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate; hypromellose; titanium dioxide; macrogol 6000; purified talc; iron oxide red - solicare is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - solifenacin succinate, quantity: 5 mg - tablet, film coated - excipient ingredients: hypromellose; lactose monohydrate; maize starch; magnesium stearate; titanium dioxide; macrogol 6000; iron oxide yellow; purified talc - solicare is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - solifenacin succinate, quantity: 5 mg - tablet, orally disintegrating - excipient ingredients: hypromellose; sucralose; croscarmellose sodium; polacrilin potassium; lactose monohydrate; sodium stearylfumarate; mannitol; flavour - solicare odt is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - fluconazole -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - mirtazapine -